Journal
CARDIOVASCULAR THERAPEUTICS
Volume 30, Issue 2, Pages e81-e88Publisher
WILEY-HINDAWI
DOI: 10.1111/j.1755-5922.2010.00239.x
Keywords
Acute myocardial infarction; Streptokinase; Thrombolysis
Funding
- Genentech, Inc.
Ask authors/readers for more resources
Coronary artery disease is the single leading cause of death in the United States. Occlusion of the coronary artery was identified to be the cause of myocardial infarction almost a century ago. Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acute myocardial infarction in terms of reducing short- and long-term mortality. Newer agents including tissue plasminogen activators such as alteplase, reteplase, tenecteplase were developed subsequently. In the present era, thrombolytic therapy and primary percutaneous coronary intervention has revolutionized the way patients with acute myocardial infarction are managed resulting in significant reduction in cardiovascular death. This article provides an overview of the various thrombolytic agents utilized in the management of patients with acute myocardial infarction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available